How Little Moderna Made Big Waves In Trial Diversity

Early on, the company committed to transparency while making sure its Phase III vaccine study enrolled a population reflective of the US as a whole. Moderna talks to Scrip about the experience.

Moderna vaccine
Moderna talked to Scrip about how it ensured diversity in its Phase III COVID-19 vaccine trial • Source: Shutterstock

When it comes to improving diversity and inclusion in clinical trials, while many companies have acted in response to COVID-19 and the way the pandemic highlighted structural deficiencies across the drug-development landscape, the messenger RNA-focused biotech Moderna, Inc. made some notable strides in its vaccine development plan.

Early on, in an effort to promote transparency, Moderna became the first to publish, without redactions, the protocol for its Phase III COVE study of its COVID-19 vaccine mRNA-1273 while the study was underway

Citeline Award Nominee

Scrip is interviewing the companies shortlisted for the inaugural champion of diversity and inclusion in clinical research award, to highlight some of the best practices in this urgent area. The series kicked off with a profile of Novavax

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diversity & Inclusion

More from ESG